| Roche Pharma (Schweiz) AG - Madopar DR, Tabletten | | 53493 | | 01 | | Madopar DR | | Tabletten | | N04BA02 | | Levodopa and Decarboxylase Inhibitor | | 29.10.1996 | | |
| | Composition | | levodopum 200.000 mg, benserazidum 50.000 mg ut benserazidi hydrochloridum, hypromellosum, mannitolum, E 172 (rubrum), povidonum K 30, magnesii stearas, silica colloidalis hydrica, ricini oleum hydrogenatum, cellulosum microcristallinum, carboxymethylamylum natricum A corresp. natrium 2.9 mg, pro compresso. | | Packungsbestandteile | | Tablets | | | | | Active Agent | Dose |
|---|
| Benserazide | 50 mg | | Levodopa | 200 mg |
| | BAG: Active Agent | Dose |
|---|
| Benserazide | 50 mg | | Levodopa | 200 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| (Rubrum) | | | | Carboxymethylamylum Natricum A | | | | Cellulosum Microcristallinum | | | | E 172 | | color. | | Hypromellosum | | | | Magnesii Stearas | | | | Mannitol | | | | Povidonum K | 30 | | | Pro Compresso | | | | Ricini Oleum Hydrogenatum | | | | Silica Colloidalis Hydrica | | |
| |
| |
|
